Melina Marmarelis, MD, Thoracic Medical Oncologist, UPenn joins us for an interview about precision medicine for mesothelioma. She discusses biomarker information, such as histology (currently most valuable), but also molecular testing for mutations such as NF2, MTAP, CDKN2A that can be used when determining precision medicine treatments. Other topics discussed are BAP1 mutations, PDL1 expression, mutational burden, and oncolytic viruses.
The interview is moderated by Julie White, BSN, OCN, RN who is the patient services director at the Mesothelioma Applied Research Foundation.
Watch the video:
Melina Marmarelis, MD, MSCE, is an Innovation Faculty member at the Penn Center for Cancer
Care Innovation (PC3I), Assistant Professor at the University of Pennsylvania, Medical
Director of the Penn Medicine Mesothelioma and Pleural Disease Program, and Co-Director
of the Molecular Tumor Board at the University of Pennsylvania. She specializes in thoracic
medical oncology. Her research focuses on early phase clinical trials in lung cancer and mesothelioma,
determinants of therapy resistance and sensitivity, and molecular characteristics and testing in non-small cell lung cancer (NSCLC).
Dr. Marmarelis earned her medical degree at Harvard Medical School. She completed her
residency at Brigham and Women’s Hospital and Hematology/Oncology fellowship at the Hospital
of the University of Pennsylvania. Dr. Marmarelis is board certified in internal medicine
and medical oncology.
Our Sponsors
MesoTV is a program by the Mesothelioma Applied Research Foundation. This program is made possible by our generous sponsors: Belluck & Fox; Maune Raichle Hartley French & Mudd, LLC (MRHFM); Polaris Pharmaceutical, Bristol Myers Squibb; The Gori Law Firm
Search our previous episodes for topics/speakers of interest to you at www.curemeso.org/mesotv.
